Mirum Pharmaceuticals, Inc. (MIRM)

Market Cap	2.23B
Revenue (ttm)	379.25M
Net Income (ttm)	-77.34M
Shares Out	49.53M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	219,847
Open	45.20
Previous Close	45.28
Day's Range	44.68 - 45.66
52-Week Range	23.83 - 54.23
Beta	0.96
Analysts	Strong Buy
Price Target	62.27 (+38.35%)
Earnings Date	May 7, 2025

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 322
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRM
• Website: https://www.mirumpharma.com

Financial Performance

In 2024, Mirum Pharmaceuticals's revenue was $336.89 million, an increase of 80.76% compared to the previous year's $186.37 million. Losses were -$87.94 million, -46.18% less than in 2023.

Analyst Forecast

According to 11 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is $62.27, which is an increase of 38.35% from the latest price.

Price Target

$62.27

(38.35% upside)

Analyst Consensus: Strong Buy